The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
MHLW Raises Drug R&D, Supply Stability as FY2026 Budget Priorities
The Ministry of Health, Labor and Welfare (MHLW) is putting pharmaceutical innovation and supply resilience at the center of its FY2026 budget talks, as it prepares for a year of major drug pricing and medical fee revisions. At a July…
To read the full story
REGULATORY
- Cabinet OKs FY2026 Tax Reform Package, Creates Strategic Tech R&D Credit
January 5, 2026
- Chuikyo OKs Medical Materials Reform Outline, Price Hikes Possible for Loss-Making Devices
January 5, 2026
- MHLW FY2026 Budget Hits Record 35 Trillion Yen, Drug Discovery Support Set at 7.1 Billion Yen
January 5, 2026
- Japan Puts CEA Expansion on Hold, Sets 6-Month “Technical Discussions”
December 26, 2025
- Gist of FY2026 Drug Pricing Reform Outline
December 26, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…